Carisma Therapeutics, Inc. (NASDAQ:CARM) shareholders won’t be pleased to see that the share price has had a very rough month, dropping 26% and undoing the prior period’s positive performance. Longer-term shareholders will rue the drop in the share price, since it’s now virtually flat…